CN103768086B - 寡核苷酸螯合物的用途 - Google Patents

寡核苷酸螯合物的用途 Download PDF

Info

Publication number
CN103768086B
CN103768086B CN201410046103.1A CN201410046103A CN103768086B CN 103768086 B CN103768086 B CN 103768086B CN 201410046103 A CN201410046103 A CN 201410046103A CN 103768086 B CN103768086 B CN 103768086B
Authority
CN
China
Prior art keywords
oligonucleotide
chelate
experimenter
rep
kinds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201410046103.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN103768086A (zh
Inventor
安德鲁·瓦利恩特
米歇尔·巴齐内
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Replicor Inc
Original Assignee
Replicor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45594559&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN103768086(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Replicor Inc filed Critical Replicor Inc
Publication of CN103768086A publication Critical patent/CN103768086A/zh
Application granted granted Critical
Publication of CN103768086B publication Critical patent/CN103768086B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
CN201410046103.1A 2010-08-20 2011-08-18 寡核苷酸螯合物的用途 Expired - Fee Related CN103768086B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37525710P 2010-08-20 2010-08-20
US61/375,257 2010-08-20
CN201180035946.6A CN103052405B (zh) 2010-08-20 2011-08-18 寡核苷酸螯合物

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201180035946.6A Division CN103052405B (zh) 2010-08-20 2011-08-18 寡核苷酸螯合物

Publications (2)

Publication Number Publication Date
CN103768086A CN103768086A (zh) 2014-05-07
CN103768086B true CN103768086B (zh) 2015-10-14

Family

ID=45594559

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201410046103.1A Expired - Fee Related CN103768086B (zh) 2010-08-20 2011-08-18 寡核苷酸螯合物的用途
CN201180035946.6A Expired - Fee Related CN103052405B (zh) 2010-08-20 2011-08-18 寡核苷酸螯合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201180035946.6A Expired - Fee Related CN103052405B (zh) 2010-08-20 2011-08-18 寡核苷酸螯合物

Country Status (35)

Country Link
US (2) US8513211B2 (cg-RX-API-DMAC10.html)
EP (1) EP2605794B1 (cg-RX-API-DMAC10.html)
JP (1) JP5775581B2 (cg-RX-API-DMAC10.html)
KR (3) KR20150039873A (cg-RX-API-DMAC10.html)
CN (2) CN103768086B (cg-RX-API-DMAC10.html)
AU (1) AU2011291401B2 (cg-RX-API-DMAC10.html)
BR (1) BR112013003875B1 (cg-RX-API-DMAC10.html)
CA (2) CA2855690C (cg-RX-API-DMAC10.html)
CL (1) CL2013000445A1 (cg-RX-API-DMAC10.html)
CO (1) CO6670525A2 (cg-RX-API-DMAC10.html)
CR (1) CR20130069A (cg-RX-API-DMAC10.html)
CU (1) CU20130022A7 (cg-RX-API-DMAC10.html)
CY (1) CY1118207T1 (cg-RX-API-DMAC10.html)
DK (1) DK2605794T3 (cg-RX-API-DMAC10.html)
DO (1) DOP2013000041A (cg-RX-API-DMAC10.html)
EA (1) EA026660B1 (cg-RX-API-DMAC10.html)
EC (1) ECSP13012449A (cg-RX-API-DMAC10.html)
ES (1) ES2598556T3 (cg-RX-API-DMAC10.html)
GT (1) GT201300040A (cg-RX-API-DMAC10.html)
HR (1) HRP20161333T1 (cg-RX-API-DMAC10.html)
HU (1) HUE029521T2 (cg-RX-API-DMAC10.html)
IL (1) IL224237A (cg-RX-API-DMAC10.html)
LT (1) LT2605794T (cg-RX-API-DMAC10.html)
MX (1) MX340294B (cg-RX-API-DMAC10.html)
MY (1) MY160961A (cg-RX-API-DMAC10.html)
NZ (1) NZ606364A (cg-RX-API-DMAC10.html)
PH (1) PH12013500192B1 (cg-RX-API-DMAC10.html)
PL (1) PL2605794T3 (cg-RX-API-DMAC10.html)
PT (1) PT2605794T (cg-RX-API-DMAC10.html)
RS (1) RS55245B1 (cg-RX-API-DMAC10.html)
SG (1) SG187165A1 (cg-RX-API-DMAC10.html)
SI (1) SI2605794T1 (cg-RX-API-DMAC10.html)
SM (1) SMT201600370B (cg-RX-API-DMAC10.html)
WO (1) WO2012021985A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA201300497B (cg-RX-API-DMAC10.html)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6047270B2 (ja) 2006-08-11 2016-12-21 バイオマリン テクノロジーズ ベー．フェー． Ｄｎａリピートの不安定性に関連した遺伝的障害を治療するための方法及び手段
JP5646320B2 (ja) 2007-05-11 2014-12-24 アダイニクス， インコーポレイテッド 遺伝子発現と疼痛
NZ584793A (en) 2007-10-26 2012-05-25 Academisch Ziekenhuis Leiden Means and methods for counteracting muscle disorders
EP2119783A1 (en) 2008-05-14 2009-11-18 Prosensa Technologies B.V. Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means
CA2862628C (en) 2012-01-27 2021-08-24 Prosensa Technologies B.V. Rna modulating oligonucleotides with improved characteristics for the treatment of duchenne and becker muscular dystrophy
PT2841578T (pt) 2012-04-23 2017-08-10 Biomarin Tech Bv Resumo
RU2668136C2 (ru) * 2012-05-10 2018-09-26 Эйдинкс, Инк. Композиции для доставки активных ингредиентов
HUE054875T2 (hu) * 2012-05-18 2021-10-28 Replicor Inc Oligonukleotid kelátkomplex-polipeptid készítmények és eljárások
AR091065A1 (es) * 2012-05-18 2014-12-30 Replicor Inc Una formulacion farmaceutica que comprende un quelato de oligonucleotidos antiviral para el tratamiento de una infeccion antiviral
CN104603271B (zh) * 2012-07-03 2019-07-19 马林生物科技有限公司 用于治疗肌肉萎缩症患者的寡核苷酸
CN104837501B (zh) 2012-08-30 2018-11-02 里普利科股份有限公司 治疗乙型肝炎及丁型肝炎感染的方法
KR20170029577A (ko) 2014-07-10 2017-03-15 레플리코르 인코포레이티드 B형 간염 및 d형 간염 바이러스 감염의 치료 방법
CN106661578B (zh) 2014-08-15 2020-08-04 埃迪恩克斯股份有限公司 用于疼痛治疗的寡核苷酸诱饵
WO2016030863A1 (en) 2014-08-29 2016-03-03 Glaxosmithkline Intellectual Property Development Limited Compounds and methods for treating viral infections
JP2018513127A (ja) 2015-04-23 2018-05-24 ジェロン・コーポレーションＧｅｒｏｎ Ｃｏｒｐｏｒａｔｉｏｎ 多価カチオン塩組成物を用いたポリヌクレオチド調製方法
US11166976B2 (en) 2018-11-08 2021-11-09 Aligos Therapeutics, Inc. S-antigen transport inhibiting oligonucleotide polymers and methods
US20200147124A1 (en) * 2018-11-08 2020-05-14 Aligos Therapeutics, Inc. S-antigen transport inhibiting oligonucleotide polymers and methods
US20230250125A1 (en) 2020-04-01 2023-08-10 Janssen Biopharma, Inc. Nucleic acid polymers
WO2022109129A1 (en) * 2020-11-20 2022-05-27 Aligos Therapeutics, Inc. Conjugates of s-antigen transport inhibiting oligonucleotide polymers having enhanced liver targeting
TW202245809A (zh) 2020-12-18 2022-12-01 美商詹森藥物公司 用於治療b型肝炎病毒感染之組合療法
WO2022152869A1 (en) 2021-01-15 2022-07-21 Janssen Sciences Ireland Unlimited Company Use of oligonucleotides for individuals with hepatic impairment
JP2024521897A (ja) * 2021-06-02 2024-06-04 アタランタ セラピューティクス，インコーポレーテッド 治療用オリゴヌクレオチドを中枢神経系に送達するための組成物及び方法
CN117616121A (zh) 2021-07-09 2024-02-27 葛兰素史密斯克莱知识产权(第3号)有限公司 寡核苷酸用于具有肾脏损伤的个体的用途
EP4728073A1 (en) * 2023-06-16 2026-04-22 Ractigen Therapeutics Oligonucleotide formulation

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6011143A (en) * 1997-09-12 2000-01-04 Canon Kabushiki Kaisha Artificial nucleic acids and a method of making
US20070105116A1 (en) * 2003-09-02 2007-05-10 Japan Science And Technology Agency Metal complex type nucleic acid

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2300938A1 (en) * 1997-08-20 1999-02-25 Somagenics, Inc. Antisense and antigene therapeutics with improved binding properties and methods for their use
US6653467B1 (en) * 2000-04-26 2003-11-25 Jcr Pharmaceutical Co., Ltd. Medicament for treatment of Duchenne muscular dystrophy
JP4836366B2 (ja) * 2000-08-25 2011-12-14 雅文 松尾 デュシェンヌ型筋ジストロフィー治療剤
WO2005026188A1 (ja) * 2003-09-08 2005-03-24 Japan Science And Technology Agency 金属錯体型核酸
WO2007005626A1 (en) * 2005-07-01 2007-01-11 Bioveris Corporation Compositions and methods for detecting, amplifying, and/or isolating nucleic acids
WO2009065181A1 (en) * 2007-11-21 2009-05-28 Apollo Life Sciences Limited Nanostructures suitable for delivery of agents

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6011143A (en) * 1997-09-12 2000-01-04 Canon Kabushiki Kaisha Artificial nucleic acids and a method of making
US20070105116A1 (en) * 2003-09-02 2007-05-10 Japan Science And Technology Agency Metal complex type nucleic acid

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Influence of divalent cations on the conformation of phosphorothioate oligodeoxynucleotides: a circular dichroism study;Siddhesh D. Patil and David G. Rhodes;《Nucleic Acids Research》;20001231;第28卷(第12期);第2439-2445页 *
反义寡核苷酸的体内研究;Akhtar S. et al.;《Foreign Medical Sciences Section on Pharmacy》;19971231;第24卷(第6期);第327-330页 *
反义寡核苷酸研究进展;陈星云;《国外医学分子生物学分册》;20001231;第22卷(第4期);第236-240页 *

Also Published As

Publication number Publication date
MX2013001668A (es) 2013-07-22
HUE029521T2 (en) 2017-03-28
KR101606495B1 (ko) 2016-03-28
JP2013536195A (ja) 2013-09-19
CL2013000445A1 (es) 2013-11-22
ES2598556T3 (es) 2017-01-27
CA2806616A1 (en) 2012-02-23
JP5775581B2 (ja) 2015-09-09
ZA201300497B (en) 2013-09-25
EA201300259A1 (ru) 2013-12-30
US8513211B2 (en) 2013-08-20
EA026660B1 (ru) 2017-05-31
SMT201600370B (it) 2016-11-10
BR112013003875B1 (pt) 2021-10-05
US8716259B2 (en) 2014-05-06
AU2011291401A1 (en) 2013-01-10
HRP20161333T1 (hr) 2016-12-02
CN103052405A (zh) 2013-04-17
EP2605794B1 (en) 2016-07-20
RS55245B1 (sr) 2017-02-28
IL224237A (en) 2015-09-24
PL2605794T3 (pl) 2017-01-31
KR20150082685A (ko) 2015-07-15
CR20130069A (es) 2013-09-20
US20130296410A1 (en) 2013-11-07
KR20150039873A (ko) 2015-04-13
US20120046348A1 (en) 2012-02-23
SG187165A1 (en) 2013-02-28
HK1184058A1 (zh) 2014-01-17
PH12013500192B1 (en) 2018-11-23
MX340294B (es) 2016-07-04
CU20130022A7 (es) 2013-04-19
MY160961A (en) 2017-03-31
CA2855690A1 (en) 2012-02-23
KR20130099067A (ko) 2013-09-05
CA2855690C (en) 2015-08-25
PH12013500192A1 (cg-RX-API-DMAC10.html) 2013-03-11
AU2011291401B2 (en) 2014-11-27
WO2012021985A1 (en) 2012-02-23
CA2806616C (en) 2015-08-11
ECSP13012449A (es) 2013-04-30
LT2605794T (lt) 2016-10-25
GT201300040A (es) 2014-09-02
HK1198123A1 (en) 2015-03-13
CN103052405B (zh) 2015-11-25
PT2605794T (pt) 2016-10-25
DOP2013000041A (es) 2017-12-15
NZ606364A (en) 2014-12-24
DK2605794T3 (en) 2016-10-24
EP2605794A4 (en) 2014-07-02
CO6670525A2 (es) 2013-05-15
BR112013003875A2 (en) 2018-03-13
CY1118207T1 (el) 2017-06-28
CN103768086A (zh) 2014-05-07
EP2605794A1 (en) 2013-06-26
SI2605794T1 (sl) 2017-01-31

Similar Documents

Publication Publication Date Title
CN103052405B (zh) 寡核苷酸螯合物
JP6294308B2 (ja) オリゴヌクレオチドキレート錯体方法
HK1198123B (en) The use of oligonucleotide chelate complexes
HK1184058B (en) Oligonucleotide chelate complexes
HK1206259B (en) Oligonucleotide chelate complex methods

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1198123

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1198123

Country of ref document: HK

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20151014